Admit Therapeutics is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Admit's blood-based assay detects beta-amyloid presence and predicts Alzheimer's progression to dementia, but commercial viability hinges on actionability — currently limited by lack of disease-modifying treatments and personalized intervention evidence.